BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Company News  |  Deals

Isotechnika, Paladin, ILJIN deal

Paladin granted Isotechnika rights to develop and commercialize voclosporin for psoriasis and transplant indications in Latin and Central America. Paladin received $1 million up front and is eligible for royalties. Paladin said Isotechnika would sublicense rights in the territories to ILJIN's ILJIN Life Science Co. Ltd....

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >